Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
217.51
+4.00 (+1.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
37
38
Next >
Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises
May 03, 2023
Eli Lilly is focusing on proteins associated with Alzheimer's disease.
Via
Investor's Business Daily
Microsoft, Snap And 2 Other Stocks Insiders Are Selling
May 03, 2023
The S&P 500 closed lower more than 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Biotech Is Back With Guggenheim Upgrade: What You Need To Know
May 01, 2023
Guggenheim Partners upgraded shares of Biogen Inc (NASDAQ: BIIB) to Buy, citing the company's potential for growth driven by its Alzheimer's disease (AD) and major depressive disorder (MDD)...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
May 01, 2023
Via
Benzinga
Looking At Biogen's Recent Unusual Options Activity
April 28, 2023
Via
Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today
April 26, 2023
Via
Benzinga
Biogen Earnings Perspective: Return On Capital Employed
April 26, 2023
Via
Benzinga
Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock
May 01, 2023
Wood is betting that Ginkgo Bioworks' biofoundry can scale up enough to become profitable.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
April 28, 2023
Via
Benzinga
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
April 28, 2023
Microsoft, Meta, Cloudflare and Crocs were among the many big movers.
Via
Investor's Business Daily
These Analysts Revise Price Targets On Biogen Following Q1 Results
April 26, 2023
Biogen Inc. (NASDAQ: BIIB) reported results for its first quarter.
Via
Benzinga
Biogen On The Hunt
April 25, 2023
Biogen is in the process of culling its pipeline to prepare for its upcoming deal making. What is happening and what does it mena?
Via
Talk Markets
Earnings Outlook For Biogen
April 24, 2023
Via
Benzinga
What Does Biogen's Debt Look Like?
April 19, 2023
Via
Benzinga
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
April 28, 2023
Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023
Via
InvestorPlace
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
April 26, 2023
The FDA approved Biogen Inc's (NASDAQ:
Via
Benzinga
Alphabet To Rally Around 36%? Here Are 10 Other Analyst Forecasts For Wednesday
April 26, 2023
Morgan Stanley raised the price target for Alphabet Inc. (NASDAQ: GOOGL) from $135 to $140. Morgan Stanley analyst Brian Nowak maintained an Overweight rating. Alphabet shares fell 1% to $102.83 in...
Via
Benzinga
What's Going On With Biogen Stock Tuesday?
April 25, 2023
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.
Via
Benzinga
Biogen Inc. Beats Q1 Earnings And Revenue Estimates
April 25, 2023
Biogen Inc. came out with quarterly earnings of $3.40 per share.
Via
Talk Markets
P/E Ratio Insights for Biogen
April 19, 2023
Via
Benzinga
Is Biogen Stock a Buy Now?
April 18, 2023
The company's fascinating saga in the Alzheimer's disease drug market continues.
Via
The Motley Fool
Leqembi Sales To Propel Biogen Stock To New Heights, Says Bullish Analyst
April 17, 2023
Via
Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
April 25, 2023
Via
Benzinga
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
April 25, 2023
The company is hopeful for maintenance dosing and a new injection of the drug.
Via
Investor's Business Daily
3 Top Biotech Stocks Defying the Bear Market
April 25, 2023
All three companies have therapies with strong sales potential.
Via
The Motley Fool
Why Shares of Keros Therapeutics Jumped This Week
April 21, 2023
The company appointed a new director and an analyst reiterated his position on the stock.
Via
The Motley Fool
Biogen To Report Q1 Earnings: Here's What To Expect
April 21, 2023
We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%.
Via
Talk Markets
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
April 21, 2023
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid...
Via
Benzinga
Better Big Biotech Buy: Biogen vs. Vertex
April 20, 2023
One is slightly cheaper than the other.
Via
The Motley Fool
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
April 18, 2023
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.